Beyond the humoral NA immunity elicited by NA-based VLP vaccination, the modified recombinant H5M2eN1-VLP also rapidly recalled the anti-HA2 antibody response to viral infection, which provided substantial cross-protection against a different lineage of seasonal influenza virus (PR8). This evidence concerns the gene XK and viral infectious disease.